Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer After Extensive Docetaxel Treatment

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Cabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel-based Chemotherapy

Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxa...

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel tre

Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. We undertook an open-label randomised phase 3 trial i...

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK (J S de Bono FRCP); Tulane University, New Orleans, LA, USA (A O Sartor MD); Hôpital Européen Georges Pompidou, Paris, France (S Oudard MD); Istanbul University, Istanbul, Turkey (M Ozguroglu MD); Odense University Hospital, Odense, Denmark (S Hansen MD); Cliniques Universitaires Saint-Luc, Université Catholique...

Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents

Background: Cabazitaxel, abiraterone, and enzalutamide are survival-prolonging treatments in men with castration-resistant prostate cancer (CRPC) progressing following docetaxel chemotherapy. The sequential activity of these agents has not been studied and treatment sequencing remains a key dilemma for clinicians. Objective: To describe the antitumour activity of cabazitaxel after docetaxel and...